Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3065-3073

  Bourne, Christina R ^a   Bunce, Richard A ^a   Bourne, Philip C ^a   Berlin, K Darrell ^a   Barrow, Esther W ^a   Barrow, William W ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [5 [(2,4 DIAMINOPYRIMIDIN 5 YL)METHYL] 2,3 DIMETHOXYPHENYL] 1 [1 PROPYLPHTHALAZIN 2(1H) YL]PROP 2 EN 1 ONE; ARGININE; DIHYDROFOLATE REDUCTASE; METHIONINE; PHTHALAZINE DERIVATIVE; RAB 1; TRIMETHOPRIM DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS ANTHRACIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; X RAY DIFFRACTION;

BACILLUS ANTHRACIS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM; X-RAY DIFFRACTION;

EID: 67649981785     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01666-08     Document Type: Article

References (51)

1. Adams, P. D., K. Gopal, R. W. Grosse-Kunstleve, L. W. Hung, T. R. Ioerger, A. J. McCoy, N. W. Moriarty, R. K. Pai, R. J. Read, T. D. Romo, J. C. Sacchettini, N. K. Sauter, L. C. Storoni, and T. C. Terwilliger. 2004. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Sync. Rad. 11:53-55.
2. Adane, L., and P. V. Bharatam. 2008. Modelling and informatics in the analysis of P. falciparum DHFR enzyme inhibitors. Curr. Med. Chem. 15:1552-1569.
3. Appleman, J. R., W. A. Beard, T. J. Delcamp, N. J. Prendergast, J. H. Freisheim, and R. L. Blakley. 1990. Unusual transient- and steady-state kinetic behavior is predicted by the kinetic scheme operational for recombinant human dihydrofolate reductase. J. Biol. Chem. 265:2740-2748.
4. Baccanari, D. P., and L. F. Kuyper. 1993. Basis of selectivity of antibacterial diaminopyrimidines. J. Chemother. 5:393-399.
5. Baker, N. A., D. Sept, S. Joseph, M. J. Holst, and J. A. McCammon. 2001. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98:10037-10041.
6. Barrow, E. W., P. C. Bourne, and W. W. Barrow. 2004. Functional cloning of Bacillus anthracis DHFR and confirmation of natural resistance to trimethoprim. Antimicrob. Agents Chemother. 48:4643-4649.
7. Barrow, E. W., J. Dreier, S. Reinelt, P. C. Bourne, and W. W. Barrow. 2007. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis. Antimicrob. Agents Chemother. 51:4447-4452.
8. Barrow, E. W., W. J. Suling, L. E. Seitz, R. C. Reynolds, and W. W. Barrow. 2006. New antifolate inhibitors for Mycobacterium avium. Med. Chem. 2:505-510.
9. Beierlein, J. M., K. M. Frey, D. B. Bolstad, P. M. Pelphrey, T. M. Joska, A. E. Smith, N. D. Priestley, D. L. Wright, and A. C. Anderson. 2008. Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase. J. Med. Chem. 51:7532-7540.
10. Bennett, B. C., H. Xu, R. F. Simmerman, R. E. Lee, and C. G. Dealwis. 2007. Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase. J. Med. Chem. 50:4374-4381.
11. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic Acids Res. 28:235-242.
12. Bock, R. A., J. L. Soulages, and W. W. Barrow. 2007. Substrate and inhibitor specificity of Mycobacterium avium dihydrofolate reductase. FEBS J. 274:3286-3298.
13. Bowden, K., N. V. Harris, and C. A. Watson. 1993. Structure-activity relationships of dihydrofolate reductase inhibitors. J. Chemother. 5:377-388.
14. Bruker. 2006. Proteum 2 Software Suite. Bruker AXS, Inc., Madison, WI.
15. Collaborative Computational Project. 1994. Collaborative computational project, number 4: the CCP4 suite: programs for protein crystallography. Acta Crystallogr. D50:760-763.
16. Champness, J. N., A. Achari, S. P. Ballantine, P. K. Bryant, C. J. Delves, and D. K. Stammers. 1994. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 Å resolution. Structure 2:915-924.
17. Cody, V., D. Chan, N. Galitsky, D. Rak, J. R. Luft, W. Pangborn, S. F. Queener, C. A. Laughton, and M. F. Stevens. 2000. Structural studies on bioactive compounds. 30. Crystal structure and molecular modeling studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate. Biochemistry 39:3556-3564.
18. Cody, V., N. Galitsky, J. R. Luft, W. Pangborn, A. Rosowsky, and R. L. Blakley. 1997. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry 36:13897-13903.
19. Cody, V., N. Galitsky, D. Rak, J. R. Luft, W. Pangborn, and S. F. Queener. 1999. Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+. Biochemistry 38:4303-4312.
20. Cody, V., J. R. Luft, and W. Pangborn. 2005. Understanding the role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr. D61:147-155.
21. Cody, V., J. Pace, K. Chisum, and A. Rosowsky. 2006. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim) derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions. Proteins 65:959-969.
22. Cody, V., J. Pace, and A. Rosowsky. 2008. Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2′- hydroxydibenz[b,f]azepin-5-yl)methylpteridine. Acta Crystallogr. D 64:977-984.
23. Dale, G. E., D. Broger, A. D'Arcy, P. G. Hartman, R. DeHoogt, S. Jolidon, I. Kompis, A. M. Labhardt, H. Langen, H. Locher, M. G. Page, D. Stüber, R. L. Then, B. Wipf, and C. Oefner. 1997. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 266:23-30.
24. Dann, J. G., G. Ostler, R. A. Bjur, R. W. King, P. Scudder, P. C. Turner, G. C. Roberts, and A. S. Burgen. 1976. Large-scale purification and characterization of dihydrofolate reductase from a methotrexate-resistant strain of Lactobacillus casei. Biochem. J. 157:559-571.
25. Darrell, J. H., L. P. Garrod, and P. M. Waterworth. 1968. Trimethoprim: laboratory and clinical studies. J. Clin. Pathol. 21:202-209.
26. Edman, K., A. Royant, G. Larsson, F. Jacobson, T. Taylor, D. van der Spoel, E. M. Landau, E. Pebay-Peyroula, and R. Neutze. 2004. Deformation of helix C in the low temperature L-intermediate of bacteriorhodopsin. J. Biol. Chem. 279:2147-2158.
27. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D60:2126-2132.
28. Finland, M., and E. H. Kass. 1973. Symposium on trimethoprim-sulfamethoxazole. J. Infect. Dis. 128:S425-S816.
29. Gasteiger, E., A. Gattiker, C. Hoogland, I. Ivanyi, R. D. Appel, and A. Bairoch. 2003. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31:3784-3788.
30. Guerry, P., C. Hubschwerlen, S. Jolidon, J.-L. Specklin, and P.-C. Wyss. 1998. Preparation of N-[(2,4-diaminopyrimidinylmethyl) cinnamoyl]phthalazines as bactericides. World patent WO9839328.
31. Guerry, P., C. Hubschwerlen, S. Jolidon, J.-L. Specklin, and P.-C. Wyss. September, 2000. Substituted 2,4-diaminopyrimidines. U.S. patent 6,114,330.
32. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharm. 71:941-948.
33. Hitchings, G. H., Jr. 1989. Nobel lecture in physiology or medicine-1988. Selective inhibitors of dihydrofolate reductase. In Vitro Cell. Dev. Biol. 25:303-310.
34. Huovinen, P., L. Sundström, G. Swedberg, and O. Sköld. 1995. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
35. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
36. Joska, T. M., and A. C. Anderson. 2006. Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads. Antimicrob. Agents Chemother. 50:3435-3443.
37. Kongsaeree, P., P. Khongsuk, U. Leartsakulpanich, P. Chitnumsub, B. Tarnchompoo, M. D. Walkinshaw, and Y. Yuthavong. 2005. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc. Natl. Acad. Sci. USA 102:13046-13051.
38. Li, R., R. Sirawaraporn, P. Chitnumsub, W. Sirawaraporn, J. Wooden, F. Athappilly, S. Turley, and W. G. J. Hol. 2000. Three-dimensional structure of Mycobacterium tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295:307-323.
39. Maskell, J. P., A. M. Sefton, and L. M. Hall. 2001. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1104-1108.
40. Molina, J. R. 2008. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 11:508-521.
41. Nimgirawath, S. 1994. Synthesis of (±)-isoautumnaline and (±)-dysoxyline. Aust. J. Chem. 47:957-962.
42. Rosowsky, A., R. A. Forsch, and S. F. Queener. 2003. Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem. 46:1726-1736.
43. Rosowsky, A., R. A. Forsch, and S. F. Queener. 2002. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy) benzyl] pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J. Med. Chem. 45:233-241.
44. Sawaya, M. R., and J. Kraut. 1997. Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry 36:586-603.
45. Sirawaraporn, W., J. C. Edman, and D. V. Santi. 1991. Purification and properties of recombinant Pneumocystis carinii dihydrofolate reductase. Protein Expr. Purif. 2:313-316.
46. Sobolev, V., A. Sorokine, J. Prilusky, E. E. Abola, and M. Edelman. 1999. Automated analysis of interatomic contacts in proteins. Bioinformatics 15:327-332.
47. Stuart, A., T. Paterson, B. Roth, and E. Aig. 1983. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 6. A one-step synthesis of new trimethoprim derivatives and activity analysis by molecular modeling. J. Med. Chem. 26:667-673.
48. Whitlow, M., A. J. Howard, D. Stewart, K. D. Hardman, J. H. Chan, D. P. Baccanari, R. L. Tansik, J. S. Hong, and L. F. Kuyper. 2001. X-ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. J. Med. Chem. 44:2928-2932.
49. Whitlow, M., A. J. Howard, D. Stewart, K. D. Hardman, L. F. Kuyper, D. P. Baccanari, M. E. Fling, and R. L. Tansik. 1997. X-ray crystallographic studies of Candida albicans dihydrofolate reductase: high-resolution structures of the holoenzyme and an inhibited ternary complex. J. Biol. Chem. 272:30289-30298.
50. Whitmore, F. C., H. Mosher, R. R. Adams, R. B. Taylor, E. C. Chapin, C. Weisel, and W. Yanko. 1944. Basically substituted aliphatic nitriles and their catalytic reduction to amines. J. Am. Chem. Soc. 66:725-731.
51. Zinner, S. H. 2007. Antibiotic use: present and future. New Microbiol. 30:321-325.